CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 309 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01759251
NCT01759251N/ACompleted

Post-marketing Observational Program of Betaserc® (Betahistine Dihydrochloride) to Evaluate Effectiveness in Patients With Vestibular Vertigo in Routine Practice

Abbott·observational·Posted Jan 3, 2013·Updated Feb 27, 2015

In Brief

An observational study for Vertigo. Completed, enrolled 309 participants across 24 sites in 2 countries.

Detailed Summary

The purposes of this international post-marketing observational program is to investigate effectiveness of betahistine dihydrochloride (Betaserc®) tablets and assess the course of vestibular vertigo after treatment discontinuation in population of Russia and Ukraine outpatients suffering from vestibular vertigo in pragmatic clinical settings. Exploratory analyses of results from both participating countries may be expected to provide insights about the subjective circumstances of vestibular vertigo patients in a wider than usual range of gender, underlying ICD-10 diagnosis, national and cultural situations.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsVertigo
CountriesRussia, Ukraine
Collaborators--

Timeline

N/ACompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedJan 3, 2013
Enrollment StartJan 1, 2013
Primary CompletionMay 1, 2014
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 13.5 years ago